JAMA DermRCT
Skin-Specific Outcomes of Brepocitinib in Patients With Dermatomyositis
Secondary Analysis of a Phase 3 Randomized Clinical Trial.
ConclusionIn this secondary analysis of a randomized clinical trial in dermatomyositis, once-daily brepocitinib, 30 mg, resulted in rapid, durable, and remission-level control of skin disease with an acceptable safety profile.
Mangold AR, Haemel A, … senior author Werth VPJAMA Dermatology